Hutchmed gastric cancer drug meets main goal in pivotal study

HUTCHMED (NASDAQ:HCM) announced that its targeted oncology candidate, savolitinib, achieved its primary endpoint in a registration-enabling Phase II trial for patients with a specific type of advanced gastric cancer.

The data will form part of a broader clinical showcase by the biopharmaceutical company at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The study evaluated the efficacy of savolitinib in patients presenting with MET-amplified gastric or gastroesophageal junction (GEJ) adenocarcinoma.

According to an Independent Review Committee assessment, the trial reached an objective response rate of 32.3 percent.

Secondary survival metrics from the data cut-off showed a disease control rate of 63.1 percent, a median progression-free survival of 4 months, and a median duration of response extending to 9.7 months.

The median time to response for participating patients was 1.4 months.

These clinical findings serve as the baseline support for Hutchmed’s New Drug Application to the China National Medical Products Administration.

The regulatory submission was accepted and granted priority review status in December 2025.

Alongside the oral presentation for savolitinib, the company intends to disclose updated clinical outcomes for its other oncology assets, including fruquintinib and surufatinib, across various tumor indications during the medical conference running from May 29 to June 2.